Market Overview

UPDATE: Piper Jaffray Initiates LipoScience at Overweight Colesterol Test Opportunity

Related LPDX
Benzinga's M&A Chatter for Thursday September 25, 2014
Stocks Smashed As Dollar Strengthens

Piper Jaffray initiated LipoScience (NASDAQ: LPDX) with an Overweight rating rating and a $15.00 price target.

Piper Jaffray noted, "Going forward, we anticipate ongoing traction converting the ~78M domestic LDL-C patient monitoring assays (~$1.8B market) to LDL-P and would note ~11% penetration (in line with North Carolina) represents a ~$330M annual revenue run-rate for LPDX. We believe LipoScience is positioned to meet and potentially beat our forward top and bottom-line projections and we are buyers of LPDX shares at current levels."

LipoScience closed at $11.00 on Friday.

Latest Ratings for LPDX

DateFirmActionFromTo
Aug 2013Piper JaffrayDowngradesOverweightNeutral
Feb 2013UBSInitiates Coverage onNeutral
Feb 2013Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for LPDX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Analyst Ratings

 

Related Articles (LPDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional